作者
Xieraili Malajiang,Wan er Shen,Alimu Aersilan,Mengzi Liu,Yuan Liang,Shengyi Wang,Saifuding Abula,Adelijiang Wusiman
摘要
Objective The aim of this study was to assess the therapeutic effects and underlying mechanisms of Dahuang Gancao Dandelion Decoction (DGD-D) on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in a mice model, with an emphasis on modulation of gut microbiota and intestinal metabolites, maintenance of intestinal barrier integrity, and inhibition of inflammatory signaling pathways. Methods Ultra-high-performance liquid chromatography with quadrupole electrospray ionization mass spectrometry (UHPLC-QE-MS) was used to examine the DGD-D, which was prepared from 40 g rhubarb, 10 g licorice, and 10 g dandelion. Potential routes and targets were found using network pharmacology. Six male C57BL/6 mice per group were randomized into control, DSS, DGD-D, and mesalazine (5-ASA) groups. UC was induced with 3% DSS for 7 days, with DGD-D administered prophylactically at 1950 mg/kg. Evaluated parameters included colon length, spleen index, and DAI, cytokine levels (ELISA, qRT-PCR), histological changes (H&E, PAS, AB-PAS), barrier proteins (IF, IHC, qRT-PCR), gut microbiota (16S rRNA sequencing), metabolites (LC-MS) and pathway validation. Results UHPLC-QE-MS identified 418 components in DGD-D, including flavonoids (25.12%) and phenolic acids (9.33%). Network pharmacology highlighted NF-κB signaling as a key pathway. In comparison to DSS, DGD-D dramatically decreased spleen index, restored colon length, and decreased DAI scores ( P < 0.05). It increased anti-inflammatory IL-4 and IL-10 while downregulating pro-inflammatory cytokines (IL-1β, IL-6, IL-17, TNF-α, and IFN-γ) and MPO ( P < 0.01). Histologically, DGD-D attenuated intestinal epithelial damage, increased goblet cells and glycoproteins, and enhanced ZO-1, Occludin, and MUC2 expression ( P < 0.01). Microbiota analysis showed increased α-diversity, elevated Firmicutes/Bacteroidetes ratio, enriched beneficial Lachnospiraceae and Ruminococcaceae , and reduced Proteobacteria and Alcaligenaceae , Moraxellaceae and Xanthomonadaceae ( P < 0.05). Metabolomics revealed downregulation of arachidonic acid (ARA) pathway mediators (ARA, LTA4, LTB4, LTD4; P < 0.001). DGD-D inhibited TLR4/MyD88/NF-κB p65/NLRP3/5-LOX expression ( P < 0.01 or P < 0.001), suppressing NF-κB/ARA signaling. Conclusion DGD-D is a viable TCM-based treatment for UC since it improves DSS-induced UC by modifying gut microbiota and intestinal metabolites, reestablishing intestinal barrier function, and blocking the NF-κB/ARA pathway.